Funding deal

GlaxoSmithKline and University College London's Institute of Ophthalmology (IoO) have entered into a three-year collaboration to investigate new compounds to treat potentially sight-threatening disorders.

IoO will receive dedicated staff and funding as well as a range of pharmaceutical compounds, biopharmaceuticals and reagents with which to probe disease mechanisms.

Professor Philip Luthert, director of IoO, said: 'The compounds would allow Institute researchers to further investigate underlying mechanisms of disease or validate novel therapies in ophthalmology.'